Cancer Diagnostics
Doctors may use one or more approaches to diagnose cancer. These can include physical exams, laboratory tests, imaging tests, and biopsies.
For any unfamiliar terms, please visit:
https://www.cancer.gov/publications/dictionaries
This table is searchable and sortable. Just click on a company logo to go to the company website or on the ad/banner/video to see an enlarged view. Simply click outside the image to return to normal view. The first row shows what a complete listing would look like. Click here to find out how you can get a company listing.
To return to the table listing all of our Directories, click here.
How to search PMM Directories
Simply enter your search terms into the search box located at the top of each Directory and then click on the blue search icon to the right. Search terms could include the name of a medical condition, type of innovation/technology, or company name, or any terms related to the condition or innovation type that you are interested in. For example, you could enter a term such as ´app´, ´gene´, ´cancer´, ´dementia´, ´epidermolysis bullosa´, or ´Pfizer´. You can also sort each of the columns alphabetically simply by clicking on the arrows that will appear to the right of the column´s name when you hover the mouse on that cell.
| Organization | Country | Innovation | Application | Company Info | Logo | Ad/Banner/Video | Company News |
|---|---|---|---|---|---|---|---|
| Personalize My Medicine | UK | Platform for medical innovation | N/A | PMM keeps you informed about the latest advancements in medical innovation with a focus on personalized and precision medicine approaches to healthcare |  |  | Subscribe to PMM's free monthly newsletter here! |
| Abbott | United States | Vysis probe kit. Single and multicolor probe sets offer a variety of ways to identify chromosome or locus deletions, gains, or translocations that have been associated with specific types of tumors | Breast, bladder, lung cancer, and leukemia | ||||
| Accugenomics | United States | AccuGenomics Lung Cancer Risk Test | gene expression tests to diagnose and monitor cancer treatment | ||||
| Agendia | The Netherlands | The MammaPrint® test analyzes the 70 most important genes associated with breast cancer recurrence. BluePrint® test identifies the underlying biology of an individual breast cancer. The tumor is then accurately classified as one of three subtypes, which reveal valuable information about its behavior, long-term prognosis and response to systemic therapy. | Breast cancer | ||||
| Agilent | United States | Agilent Resolution ctDx FIRST is a liquid biopsy NGS assay optimized for cancer genomic profiling. ctDx FIRST is an FDA approved companion diagnostic to KRAZATI™ (adagrasib) for the detection of KRAS G12C in non-small cell lung cancer (NSCLC) and provides tumor mutation profiling for single nucleotide variants (SNVs) and deletions in the EGFR gene | Non-small cell lung cancer | ||||
| Amoy Diagnostics Co., Ltd (AmoyDx) | China | Several NGS Assays. E.g., The AmoyDx® BRCA1 and BRCA2 Gene Mutation Detection Kit (Reversible Terminator Sequencing) allows the detection of single nucleotide variants (SNVs) and insertions and deletions (Indels) from tissue-derived DNA, and the detection of SNVs, Indels, and large rearrangements (LRs) from blood-derived DNA | Qualitative detection of BRCA1 and BRCA2 to test for ovarian and breast cancer | ||||
| Amoy Diagnostics Co., Ltd (AmoyDx) | China | Several Real-time PCR Assays. E.g., The AmoyDx® Pan Lung Cancer PCR Panel is a real-time PCR assay for qualitative detection of 167 hotspot alterations in EGFR, ALK, ROS1, KRAS, BRAF, HER2, RET, MET, NTRK1, NTRK2 and NTRK3 genes | Aids in the identification of multigene status for Non-Small Cell Lung Cancer (NSCLC) patients | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Amoy Diagnostics Co., Ltd (AmoyDx) | China | HER-2 Gene Amplification Analysis Kit is a FISH assay for detection of HER-2 gene amplification and over-expression | Breast cancer, gastric cancer, prostate, ovarian cancer and uterine serous endometrial carcinoma | ||||
| Amadix | Spain | PreveCol® is an innovative test based on an algorithm that combines the clinical characteristics identified by Artificial Intelligence with the analysis of biomarker levels in plasma for the early detection of Colorectal Cancer (CRC) and advanced adenoma (AA) | Colorectal cancer and advanced adenoma | ||||
| Amadix | Spain | PancreaDix® identifies and measures biomarkers which are differentially expressed in blood samples of individuals with Pancreatic Cancer (PaC) | Pancreatic cancer | ||||
| Amadix | Spain | DiagnoLung® identifies and measures proteins which are differentially expressed in blood samples of individuals with Lung Cancer | Lung Cancer | ||||
| ARNA Genomics US Inc | United States | ARNA Breast Multiomics Assay is a minimally invasive genetic test based on the analysis of free-circulating DNA in blood plasma | Breast Cancer | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| AroCell | Sweden | AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. AroCell TK 210 ELISA uses monoclonal antibodies specific for the TK1 epitope TK 210 to bring improved sensitivity and specificity to the assay of this key biomarker. | Hematological and solid tumors | ||||
| Arquer Diagnostics | United States | ADXBLADDERTM is a non-invasive test which can detect the cancer biomarker MCM5 (Minichromosome Maintenance Complex Component 5) from a simple urine sample in three hours | Bladder cancer | ||||
| Arquer Diagnostics | United States | ADXGYNAETM test – a semi-quantitative ELISA (enzyme-linked immunosorbent assay) – can rule out cancer with 99.2% accuracy from a simple urine sample in as little as three hours. | Endometrial cancer | ||||
| Asuragen | United States | QuantideX qPCR BCR-ABL IS Kit’s sensitivity coupled to a simple-to-run, singlicate test, allows labs to reliably and reproducibly monitor much deeper molecular response | Chronic Myeloid Leukemia | ||||
| Berry Oncology Copyright - Fuijan He Rui Gene Inc | China | Hefeian® provides gene mutation detection of non-small cell lung cancer by utilizing a liquid biospy as the biological specimen. Also offers many other tests. | Lung Cancer | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| BioAffinity Technologies | United States | CyPath® Lung uses flow cytometry to analyze the cells in a person’s sputum, or phlegm, to find cancer cells that have sloughed off a lung tumor during collection of the sample | Lung Cancer | ||||
| BioCaptiva | United Kingdom | BioCaptis dramatically increases the amount of cell-free DNA (cfDNA) available for liquid biopsy testing, aiding cancer diagnostics and research | Applicability of liquid biopsy from 10-15% of cancers to >95% | ||||
| Biodesix | United States | Nodify Lung® testing consists of two blood-based proteomic tests. The Nodify CDT® and Nodify XL2® tests help providers to determine the risk of malignancy of a lung nodule | Lung Cancer | ||||
| Blue Earth Diagnostics | United Kingdom | Diagnostic nuclear medicine is a type of molecular imaging that uses very small amounts of radioisotopes attached to a targeting molecule (radiopharmaceutical1). Radiopharmaceuticals are able to show the physiological function of the body rather than just the anatomy. | Not specified | ||||
| Cancer Diagnostics, Inc. (CDI) | United States | 7-dye kit to mark and identify cancer margins in tissue | Marks the margins of excised surgical specimens - Type of cancer not specified. | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Cancer Targeted Technology (CTT) | United States | CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 detects cancer that has escaped from the prostate as well as distant metastatic disease including bone metastases with greater precision and resolution than current standard of care. | Prostate Cancer; it also detects metastatic bone cancer | ||||
| Cancer Treatment Centers of America | United States | At Cancer Treatment Centers of America® (CTCA), uses sophisticated diagnostic technology to pinpoint and evaluate tumors and develop a personalized treatment plan | Not specified | ||||
| Capsulomics | United States | ENVISAGE is a test that determines which patients with pre-cancerous Barrett’s esophagus will progress to esophageal cancer in the future, empowering physicians to provide rapid treatment to prevent esophageal cancer | Barret's esophagus cancer | ||||
| Capsulomics | United States | DETECT is the only non-invasive early detection test available for detection of pre-cancerous Barrett’s esophagus, and both primary types of esophageal cancer, for early targeted, often curative intervention | Barret's esophagus cancer | ||||
| Caris Life Sciences | United States | Caris Assure™ offers a minimally-invasive option for biomarker analysis and serial monitoring of cancer patients when tissue samples are not available. It applies a novel Circulating Nucleic Acids Sequencing (cNAS) approach. | To guide personalized treatment decisions and improve patient outcomes | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| CDx Diagnostics | United States | WATS3D is their proprietary diagnostic platform for identifying pre-cancerous cells in the esophagus. It is included as an adjunct to routine biopsies for screening and surveillance of Barrett's esophagus. | Barret's esophagus cancer and low grade dysplasia identification | ||||
| CDx Diagnostics | United States | OralCDx®is a Non-Invasive Oral Brush Biopsy with AI-enabled Tissue Analysis. A routine diagnostic test that empowers doctors to help prevent oral cancer and save lives. | Oral cancer | ||||
| CDx Diagnostics | United States | EndoCDx® is an In-Office Transepithelial Laryngeal Brush Biopsy. Provides physicians with a practical method of testing non-suspicious tissue in order to help prevent laryngeal cancer. | Laryngeal cancer | ||||
| Celcuity | United States | The CELsignia test diagnoses new cancer sub-types that molecular-based approaches cannot detect. It measures the dynamic pathway signaling activity in a cancer patient's living cancer cells ex vivo. | Metastatic Breast Cancer | ||||
| CellMax Life | United States | CelMAx-CRC Colorectal Cancer Early Detection Test can detect 1 cancer cell among a billion normal cells. It requires only a routine blood draw and it is more accurate than a stool-based tests for the detection of pre-cancerous lesions. | Colorectal cancer | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| CellMax Life | United States | CellMax-Prostate Cancer blood test will assess the probability of a positive prostate biopsy, helping patients and doctors decide if a biopsy is needed. | Prostate cancer | ||||
| Cepheid | United States | Xpert is a non-invasive biomarker test with proven clinical sensitivity and specificity for low and high-grade bladder cancer | Bladder cancer | ||||
| Cleveland Diagnostics | United States | IsoPSA is an additional test for men that helps determine whether cancer may be the cause of their elevated PSA levels. Their proprietary Solvent Interaction Analysis-based technology is tunable to detect underlying cancer biology by measuring changes in the structure of proteins. | Prostate cancer | ||||
| Clinical Genomics | Australia | InSure® ONE™ is a fecal immunochemical test (FIT) that is performed using toilet water collected from a single bowel movement | Colorectal cancer | ||||
| Devyser Diagnostics | Sweden | The Devyser HBOC gene panel can be employed as a first-line protocol simultaneously with BRCA1 and BRCA2, extending the screening by an additional 12 genes. | Hereditary breast and ovarian cancer. | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Devyser Diagnostics | Sweden | Devyser BRCA NGS reduces hands-on time from days to minutes with Devyser’s CE-IVD single tube, next-generation sequencing (NGS) library prep kit for fast and complete characterization of BRCA1 and BRCA2 | Hereditary breast and ovarian cancer | ||||
| Exact Sciences | United States | Oncoguard® Liver solution includes a sophisticated, yet simple, single blood test that delivers advanced sensitivity and specificity to aid consistent and reliable HCC detection. The test is complemented by a Patient Engagement Program. | Liver cancer | ||||
| Epigenomics AG | Germany | Epi proColon® offers a convenient way of detecting colorectal cancer, from a blood sample. It detects a specific type of DNA called Septin9 | Colorectal cancer | ||||
| Flagship Bioscience | United States | TissueInsight® diagnostic service offers access to data for advanced patient care. Provides the most accurate and precise tissue scoring available. | Not stated | ||||
| Foresight Diagnostics | United States | Foresight’s peer-reviewed and proprietary minimal residual disease (MRD) technology detected circulating tumor DNA in all the patients who would relapse at the end of therapy | B-cell malignancies, lung cancer, and breast cancer | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Foundation Medicine | United States | FoundationOne CDx results include microsatellite instability (MSI) and tumor mutational burden (TMB) to help inform immunotherapy decisions, and loss of heterozygosity (LOH) | Ovarian cancer | ||||
| Foundation Medicine | United States | FoundationOne Liquid CDx is a companion diagnostic that analyzes guideline-recommended genes from a simple blood draw | Solid Tumors | ||||
| Freenome | United States | Freenome’s multiomics integrates assays for cell-free DNA, methylation, and proteins with advanced computational biology and machine learning techniques | Colorectal Cancer Detection | ||||
| GENECAST | South Korea | The ADPS™ EGFR Mutation Test kit v1 is a real–time PCR assay for qualitative detection of 44 somatic mutations in exons 18-21 of the EGFR gene | Non-small cell lung cancer (NSCLC) | ||||
| Genecast | China | Genecast Hereditary (FAM) is an NGS-based early screening test for multi-gene identification of over 50 types of hereditary cancer syndromes in 25 solid tumors | Solid Tumors | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| GeneFirst | United Kingdom | The XCeloSeq (Pan, Colon, Lung, Breast) cfDNA Kit Enrichment Kits generate high quality sequencing libraries for cancer detection from liquid biopsy (cfDNA) samples or FFPE-preserved material | Pancreatic, colon, lung and breast cancer | ||||
| GeneFirst | United Kingdom | A variety of specific XCeloSeq Targeted RNA Enrichment Kits generate high quality sequencing libraries for detection of cancer-related gene fusion events from FFPE-preserved material | Lung cancer, solid cancer, sarcoma, myeloid, lymphoma and actute lymphoblastic leukemia. | ||||
| GEN inCode | United Kingdom | The ROCA Test is a blood test that determines the risk of a woman having ovarian cancer. The test is intended for women with a mutation in the BRCA1 or BRCA2 gene that confers a high risk of developing ovarian cancer. | Ovarian Cancer | ||||
| Geneseeq | Canada | Essencare™CDx includes EGFR/ALK/ROS1/BRAF/KRAS/HER2 mutation testing kit are companion diagnostic tests in vitro, used in parallel to a therapeutic product | Non-small cell lung cancer (NSCLC) | ||||
| Geneseeq | Canada | GENESEEQPRIME™ analyzes 437 cancer-related genes by next-generation sequencing. GENESEEQPRIME™HRD nalyzes homologous recombination deficiency (HRD)-related genomic instabilities and detects 437 cancer-relevant genes. GeneseeqLite™ targets major actionable solid tumor genes | Solid Tumors | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Genetron Health | China | Genetron Health's IVD platform provides solutions for molecular diagnosis by using core fluorescent quantitative PCR, digital PCR, and high-throughput sequencing (NGS) systems | Lung, brain, liver, colon, stomach, thyroid, breast, bladder | ||||
| GRAIL | United States | The Galleri test detects a cancer signal shared by more than 50 types of cancer through a simple blood draw. Including cancers not routinely screened for today, to allow for earlier treatment. It should be used in addition to routine screening. | 50 types of cancer, for more information click on: https://www.galleri.com/the-galleri-test/types-of-cancer-detected | ||||
| Guardant Health | United States | Guardant360 provides guideline-recommended genomic results in 7 days from a routine blood draw, eliminating the need to solely rely on tissue testing | Non-small cell lung cancer (NSCLC) and all solid cancers | ||||
| HCA Healthcare Uk | United Kingdom | Sarah Cannon Molecular Diagnostics is part of HCA Healthcare UK and provides a range of genomic tests using next generation sequencing (NGS) technology | Solid tumours: in common cancers including lung, colorectal, breast, and melanoma | ||||
| Hologic Inc. | United States | CancerTYPE ID is a gene expression assay that helps physicians achieve a definitive diagnosis for metastatic patients when the tumor’s origin is uncertain | Cancers of Unkown Primary (CUP) | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| INOVIQ Ltd (Asx:IIQ) | United Kingdom | hTERT ICC assay is an immunohistochemistry test to use in adjunction to urine cytology testing for bladder cancer | Bladder cancer | ||||
| INOVIQ Ltd (Asx:IIQ) | United Kingdom | BARD1 autoantibody tests measure autoantibodies to variant BARD1 proteins in the blood and use a proprietary cancer-specific algorithm to identify the presence or absence of a cancer | Breast, Ovarian, and Lung cancer | ||||
| INOVIQ Ltd (Asx:IIQ) | United Kingdom | SubB2M is an engineered protein that binds to a unique sugar molecule called Neu5Gc which is only present in human cancers | Breast, Ovarian, Prostate, Colon, Lung, Pancreatic, and Endometrial cancer | ||||
| Invitae Corp | United States | Invitae offers a number of tests focused on specific types of cancer including, but not limited to hereditary cancer genetic screening tests | Breast, ovarian, uterine, endometrial, skin, prostate, pancreatic, gastric, renal cell, thyroid, and pediatric cancer | ||||
| Inspirata | United States | Dynamyx streamlines case management by exploiting advances in image digitization and solution interoperability to ensure the accelerated return of patient results | It is a software rather than a test - cancer type not specified | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Immucura diagnostics | United Kingdom | This unique cancer diagnostics program is designed to provide early detection of tumors far quicker than traditional methods to allow for more time to halt and prevent the spread of cancer in the body to fast track recovery | Breast cancer and prostate cancer | ||||
| Menarini Silicon Biosystems x CellSearch | Italy / United States | CELLSEARCH® Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells (CTC) of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+) in whole blood. The kit is used in conjunction with the CELLSEARCH Circulating Tumor Cell Control Kit. | Metastatic breast, prostate, or colorectal cancer | ||||
| Mirada Medical | United Kingdom | Mirada Diagnostic Imaging Software represents a complete departmental solution for advanced diagnostic reading. Tools to help achieve confidence in reading and data interpretation. | Not specified | ||||
| Natera | United States | Signatera™ is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools | Colorectal, Bladder, Breast Skin, Lung, Gynaecologic cancers | ||||
| NeoGenomics | United States | A comprehensive testing menu of over 650 tests that encompass all major testing methodologies – flow cytometry, FISH, cytogenetics, and targeted or broad-panel DNA- and RNA-based next-generation sequencing (NGS) | Tissue-based and liquid biopsy testing of solid tumor and hematologic cancers | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| OncoDNA-BioSequence | Spain | OncoDEEP is a unique solution that combines the study of DNA, RNA, and proteins from a solid biopsy | Solid tumors or pediatric glioblastoma | ||||
| OncoDNA-BioSequence | Spain | OncoSELECT is a molecular study for all kinds of solid tumors in later stages. It analyses 58 genes from a liquid biopsy (SNVs, Indels, Gene Fusions and Unusual Splicing) via Next Generation Sequencing | Stage III-IV solid tumors | ||||
| OncoDNA-BioSequence | Spain | OncoFOLLOW a personalized study based from a liquid biopsy. It is a new genomic study that allows for the dectection and monitorization of mutations from circulating tumor DNA (ctDNA) | Adult patients with solid stage IV solid tumors that have been previously sequenced (with OncoDEEP or another test) | ||||
| Panakeia | United Kingdom | PANProfiler Breast (ER, PR, HER2), Breast cancer diagnostic tool that reports tissue ER, PR, HER2 status by analysing H&E slides | Breast cancer | ||||
| Pillar Biosciences | United States | The oncoReveal™ Dx Lung allows for the test to be used as a companion diagnostic (CDx) for all FDA approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapies for NSCLC targeting EGFR mutations (Exon 19 In Frame Deletions and Exon 21 L858R Substitution Mutations) | Non-small cell lung cancer | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Pillar Biosciences | United States | The Colon Cancer Assay PMA allos for the test to be used as a companiong idagnostic (CDx) for KRAS wild-type tumor tissue (absence of mutations in codons 12 and 13) for metastatic colorectal cancer (mCRC) patients | Metastatic colorectal cancer | ||||
| Qiagen | Germany | Therascreen Solid Tumour portfolio of assays enables rapid and sensitive detection for oncogene analyses. Reliable detection and quantification of mutations and other cancer related genomic variants requires. The portfolio includes assays for both FFPE and liquid biopsy analysis. | Solid tumors in ovary, breast, lung, brain, and stomach | ||||
| Qiagen | Germany | Ipsogen Leukemia provides sensitive and reliable detection and quantitative, qualitative or semi-quantitative analysis of a range of blood cancer biomarkers, enabling you to unlock new insights | Leukemia | ||||
| Roche | Switzerland | In vitro diagnostics, instruments, and digital solutions | Lung, Breast, Haematology, Liver, Skin and Cervical cancer | ||||
| ThermoFisher Scientific | United States | The Oncomine™ Lung cfDNA Assay is part of a complete research solution to detect lung tumor-derived DNA (ctDNA) in cfDNA | Lung cancer | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Varex Imaging | United States / Germany | Varex Imaging provides a range of OEM X-RAY TUBES to aid in the diagnosis of different types of cancers | Not specified | ||||
| Veracyte | United States | Veracyte provides RNA whole-transcriptome sequencing, in vitro diagnostic testing and genomic sequencing classifier (GSC) tests (Proprietary tests include AFIRMA® , DECIPHER® , PROSIGNA® , PERCEPTA® ) | thyroid, prostate, bladder, breast, and lung cancer | ||||
| Zeesan | United States | MeltPro® High Risk HPV Genotyping Assay is a qualitative in vitro test that uses cervical cells collected by swab, TCT or LCT. This test utilizes Polymerase Chain Reaction (PCR) for DNA amplification and nucleic acid hybridization for the detection of high-risk HPV types in one reaction. | HPV genotyping and cervical cancer screening | ||||
| Zeesan | United States | Detection Kits (WT1, CBFβ-MYH11, PML-RARα V/S/L or AML1 ETO) aim to quantify the specific transcripts in human bone marrow or whole blood samples of leukemia patients | Leukemia | ||||
| Zeesan | United States | Leukemia Fusion Genes (Q30) kit detects RNA transcripts of fusion genes extracted from human bone marrow or whole blood samples using a RT-qPCR procedure | Screening of 30 fusion genes resulted from chromosome translocations involved in chronic and acute leukemia | The first row shows what your upgraded listing would look like. Click here to find out how you can upgrade your company's listing. | |||
| Zeesan | United States | Genotyping Kits (BCR-ABL1 or PML-RARα) detect RNA transcripts of fusion genes extracted from human bone marrow or whole blood samples with BCR-ABL1 or PML-RARα to differentiate between the three splice variants | Leukemia |